Veru (VERU) & Its Competitors Head to Head Analysis

Veru (NASDAQ:VERU) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Veru to related businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, earnings, valuation and dividends.

Insider and Institutional Ownership

47.2% of Veru shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Veru and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1	0	3	0	2.50
Veru Competitors	7777	13864	25740	1034	2.41

Veru currently has a consensus target price of $24.50, indicating a potential upside of 1,013.64%. As a group, “Pharmaceuticals” companies have a potential upside of 23.43%. Given Veru’s stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than its peers.

Profitability

This table compares Veru and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Veru Competitors	-2,381.20%	-218.66%	-15.76%

Risk & Volatility

Veru has a beta of -1.2, suggesting that its share price is 220% less volatile than the S&P 500. Comparatively, Veru’s peers have a beta of -3.76, suggesting that their average share price is 476% less volatile than the S&P 500.

Earnings & Valuation

This table compares Veru and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Veru	$16.89 million	-$22.73 million	-3.19
Veru Competitors	$3.56 billion	$3.19 billion	548.13

Veru’s peers have higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Veru beats its peers on 8 of the 12 factors compared.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.